Patient characteristics
| Baseline characteristics | Total (n=202) | With NP symptoms (n=112) | Without NP symptoms (n=90) | P value |
| Male sex, n (%) | 115 (56.9) | 64 (57) | 51 (56.7) | 0.946 |
| Age, mean (SD) | 65.0 (14.3) | 66.8 (14.1) | 62.7 (14.3) | 0.051 |
| NIHSS score, median (IQR) | 8 (3.8–16) | 9 (4–16) | 7 (3–13.2) | 0.039 |
| ICH volume*, median (IQR) | 8.3 (2.1–20) | 7.6 (1.9–19.8) | 8.9 (2.2–20.2) | 0.858 |
| Lobar ICH location, n (%) | 72 (35.6) | 39 (34.8) | 33 (36.7) | 0.786 |
| Right side ICH, n (%) | 99 (49.0) | 59 (52.7) | 40 (44.4) | 0.245 |
| Previous conditions | ||||
| Hypertension, n (%) | 128 (63.4) | 74 (66.1) | 54 (60.0) | 0.373 |
| Hypercholesterolaemia, n (%) | 65 (32.2) | 36 (32.1) | 29 (32.2) | 0.990 |
| Diabetes, n (%) | 29 (14.4) | 15 (13.4) | 14 (15.6) | 0.663 |
| Excessive alcohol consumption, n (%) | 60 (29.7) | 33 (29.5) | 27 (30.0) | 0.934 |
| Previous IS or ICH, n (%) | 25 (12.4) | 13 (11.6) | 12 (13.3) | 0.711 |
| Pre-existing dementia,† n (%) | 19 (9.4) | 14 (12.5) | 5 (5.6) | 0.089 |
| Pre-ICH functional disability,‡ n (%) | 29 (14.4) | 18 (16.1) | 11 (12.2) | 0.438 |
| Follow-up features | ||||
| Post-ICH dementia, n (%) | 48 (23.8) | 36 (32.1) | 12 (13.3) | 0.002 |
| Antidepressant drug use, n (%) | 51 (25.2) | 33 (29.5) | 18 (20.0) | 0.135 |
| Anxiolytic/hypnotic drug use, n (%) | 51 (25.2) | 30 (26.8) | 21 (23.3) | 0.606 |
| MRI features | Total (n=167) | With NP symptoms (n=94) | Without NP symptoms (n=73) | P value |
| Presence of lacunes, n (%) | 68 (40.7) | 37 (39.4) | 31 (42.5) | 0.685 |
| Presence of superficial cortical siderosis | 27 (16.2) | 17 (18.1) | 10 (13.7) | 0.427 |
| Presence of CMB, n (%) | 102 (61.1) | 62 (66.0) | 40 (54.8) | 0.142 |
| Strictly lobar | 27 (16.2) | 19 (20.2) | 8 (11.0) | 0.107 |
| Strictly deep | 17 (10.2) | 13 (13.8) | 4 (5.5) | 0.077 |
| Mixed lobar+ deep | 58 (34.7) | 30 (31.9) | 28 (38.4) | 0.386 |
| WMH Fazekas MRI score, n (%) | ||||
| 0 | 25 (15.0) | 13 (13.8) | 12 (16.4) | 0.639 |
| 1 | 42 (25.1) | 24 (25.5) | 18 (24.7) | 0.897 |
| 2 | 58 (34.7) | 32 (34.0) | 26 (35.6) | 0.832 |
| 3 | 42 (25.1) | 25 (26.6) | 17 (23.3) | 0.625 |
| Cerebral atrophy MRI score, n (%) | ||||
| 0 | 32 (19.2) | 16 (17.0) | 16 (21.9) | 0.425 |
| 1 | 57 (34.1) | 34 (36.2) | 23 (31.5) | 0.528 |
| 2 | 70 (41.9) | 40 (42.6) | 30 (41.1) | 0.850 |
| 3 | 8 (4.8) | 4 (4.3) | 4 (5.5) | 0.964 |
| CAA MRI profile, n (%) | 34 (20.4) | 17 (18.1) | 17 (23.3) | 0.408 |
*Expressed in mL.
†Defined as an Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) score ≥64.
‡Defined as an mRS score ≥3.
CAA, cerebral amyloid angiopathy; CMB, cerebral microbleeds; ICH, intracerebral haemorrhage; IQR, interquartile range; IS, ischaemic stroke; MRI, magnetic resonance imaging; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; NP, neuropsychiatric; SD, standard deviation; WMH, white matter hyperintensities.